Lantern Pharma Inc. Purchase Obligation
Lantern Pharma Inc. (LTRN) had Purchase Obligation of $2.48 million as of 2022-03-31, per its 10-Q filed 2022-05-03.
Discontinued › Notes
us-gaap:PurchaseObligation · last filed 2022-05-03
- 2022-03-31: Purchase Obligation $2.48M.
- 2021-11-30: Purchase Obligation $940.00K.
| Period end | Purchase Obligation |
|---|---|
| 2022-03-31 | $2.48M 10-Q · filed 2022-05-03 |
| 2021-11-30 | $940.00K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |